Biocept enters into laboratory services agreements with independent physician associations for full array of its Target Selector liquid biopsy oncology assays

Biocept, Inc. (NASDAQ:BIOC) (FRA:B003) said that it has entered into laboratory services agreements with independent physician associations (IPAs) providing physicians and patients in-network access to the company's full array of Target Selector liquid biopsy oncology assays and services. The group said both IPAs are headquartered in San Diego and combined, serve more than 70,000 covered lives in the Southern California region.   "We see a role for our Target Selector assays and services in value-based delivery health plans such as IPAs with goals to deliver cost-efficient and high-quality care," said Michael Nall, Biocept's president and CEO in a statement. READ: Biocept receives 150,000 samples for COVID-19 testing; completes relocation "Our Target Selector provides evidence-based, clinically actionable results that allow physicians the ability to choose individual biomarker tests or larger liquid biopsy panels to provide the best approach for each patient. Contracting with value-based providers is a priority for Biocept and we expect to enter into additional services agreements in the future," the Biocept CEO added. Biocept  is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. It uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The company's patented Target Selector liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. Additionally, Biocept is offering nationwide coronavirus (COVID-19) polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic. Contact the author at jon.hopkins@proactiveinvestors.com